Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥1,859 JPY
Change Today -36.00 / -1.90%
Volume 109.2K
4574 On Other Exchanges
As of 2:00 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

taiko pharmaceutical co ltd (4574) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/1/14 - ¥2,532
52 Week Low
08/12/14 - ¥1,543
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAIKO PHARMACEUTICAL CO LTD (4574)

Related News

No related news articles were found.

taiko pharmaceutical co ltd (4574) Related Businessweek News

No Related Businessweek News Found

taiko pharmaceutical co ltd (4574) Details

Taiko Pharmaceutical Co., Ltd. manufactures, procures, and sells non-prescription (OTC) drugs in Japan, Mainland China, Hong Kong, and Taiwan. It offers gastrointestinal drugs under the Seirogan, Seirogan TOI A, and Pishut brands for the treatment of loose stools, diarrhea, food poisoning, water poisoning, vomiting, and similar conditions; and designated quasi drugs comprising Trumpet Intestinal Regulator BF, as well as sells Hiya Kiogan, a prediatric drug. The company also manufactures and sells sanitation control products, such as Cleverin and WE'LL SHIELD; and sells LISPASS Cleverin generator, a machine which emits low concentrations of chlorine dioxide gas. In addition, it supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. Further, the company provides additives and pyroligneous acids for horticultural use. Taiko Pharmaceutical Co., Ltd. was founded in 1946 and is headquartered in Osaka, Japan.

205 Employees
Last Reported Date: 06/26/15
Founded in 1946

taiko pharmaceutical co ltd (4574) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥116.4M
Compensation as of Fiscal Year 2014.

taiko pharmaceutical co ltd (4574) Key Developments

Taiko Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2015

Taiko Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2015.

Taiko Pharmaceutical Co., Ltd. Reports Consolidated and Nonconsolidated Earnings Results for the Full Year Ended March 31, 2015; Provides Earnings Guidance for the Full Year Ending March 31, 2016

Taiko Pharmaceutical Co., Ltd. reported consolidated and nonconsolidated earnings results for the full year ended March 31, 2015. For the year, on consolidated basis, net sales were JPY 8,978 million against JPY 9,947 million a year ago. Operating income was JPY 2,559 million against JPY 2,590 million a year ago. Ordinary income was JPY 2,776 million against JPY 2,683 million a year ago. Net income was JPY 1,770 million against JPY 1,747 million a year ago. Diluted net income per share was JPY 134.47 against JPY 131.56 a year ago. Cash flows from operating activities were negative of JPY 690 million against JPY 3,589 million a year ago. On nonconsolidated basis, net sales were JPY 8,517 million against JPY 9,638 million a year ago. Operating income was JPY 2,308 million against JPY 2,230 million a year ago. Ordinary income was JPY 2,560 million against JPY 2,370 million a year ago. Net income was JPY 1,669 million against JPY 1,535 million a year ago. Diluted net income per share was JPY 126.83 million against JPY 115.63 million a year ago.

Taiko Pharmaceutical Co., Ltd. to Report Fiscal Year 2015 Results on May 13, 2015

Taiko Pharmaceutical Co., Ltd. announced that they will report fiscal year 2015 results on May 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4574:JP ¥1,859.00 JPY -36.00

4574 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4574.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4574 Industry Range
Price/Earnings 14.0x
Price/Sales 2.7x
Price/Book 1.9x
Price/Cash Flow 14.5x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAIKO PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at